Sanitam Partners exits Matinas BioPharma stake
Sanitam Partners LLC, a more than ten percent owner of Matinas BioPharma Holdings, Inc., reported restructuring transactions dated June 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Sanitam Partners LLC, a more than ten percent owner of Matinas BioPharma Holdings, Inc., reported restructuring transactions dated June 10, 2026. It disposed of Series C Convertible Preferred Stock and warrants through a distribution of its holdings to its members. Following these transactions, Sanitam no longer beneficially owns any securities of Matinas BioPharma.
Insider Trade Summary
Other: 4,800,042 shares
Other
2 txns
Insider
Sanitam Partners LLC
Role
10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Series C Convertible Preferred Stock F1, F2 | 1,406 | $0.586 | $823.92 |
| Other | Warrants to Purchase Common Stock F1 | 4,798,636 | $0.6446 | $3.09M |
Holdings After Transaction:
Series C Convertible Preferred Stock — 0 contracts (Direct);
Warrants to Purchase Common Stock — 0 contracts (Direct)
Footnotes (2)
- F1. On June 10, 2026, Sanitam Parnters LLC ("Sanitam") distributed its holdings in the Registrant's preferred stock and warrants to its members. As such Sanitam no longer beneficially owns any securities of the Registrant.
- F2. The Series C Convertible Preferred Stock of the Registrant is perpetual and has no expiration date.
Key Figures
Series C Preferred Shares Disposed: 1,406 shares
Preferred Conversion Price: $0.5860 per share
Underlying Common from Preferred: 2,399,318 shares
+5 more
8 metrics
Series C Preferred Shares Disposed
1,406 shares
Series C Convertible Preferred Stock reported as disposed on June 10, 2026
Preferred Conversion Price
$0.5860 per share
Conversion or exercise price of Series C Convertible Preferred Stock
Underlying Common from Preferred
2,399,318 shares
Common Stock underlying the Series C Convertible Preferred Stock position
Warrants Disposed
4,798,636 warrants
Warrants to Purchase Common Stock reported as disposed on June 10, 2026
Warrant Exercise Price
$0.6446 per share
Conversion or exercise price of the Warrants to Purchase Common Stock
Warrant Expiration
April 8, 2030
Expiration date of the Warrants to Purchase Common Stock
Restructuring Shares Total
4,800,042 shares
Total restructuring-related shares in transaction summary
Post-Transaction Holdings
0 securities
Total securities beneficially owned by Sanitam after distribution
Key Terms
Series C Convertible Preferred Stock, Warrants to Purchase Common Stock, beneficially owns, other acquisition or disposition, +1 more
5 terms
Series C Convertible Preferred Stock financial
"security title listed as Series C Convertible Preferred Stock"
Series C convertible preferred stock is a class of investment shares issued in a later private financing round that combine safety and upside: they usually pay ahead of ordinary shares if a company pays dividends or is sold, but can be converted into common stock to share in future growth. For investors this acts like a VIP ticket with a safety net—offering priority protection while preserving the option to participate in a successful exit.
Warrants to Purchase Common Stock financial
"security title listed as Warrants to Purchase Common Stock"
beneficially owns financial
"Sanitam no longer beneficially owns any securities of the Registrant"
Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.
other acquisition or disposition financial
"transaction code J described as Other acquisition or disposition"
perpetual financial
"The Series C Convertible Preferred Stock of the Registrant is perpetual"
Perpetual describes a financial instrument or obligation that has no fixed end date and can continue indefinitely unless the issuer chooses to end it. For investors, that means there is no scheduled return of principal, so value depends on ongoing payments, issuer stability and market interest rates—similar to receiving rent from a property with no set sale date. Perpetual instruments often pay higher yields to compensate for that open-ended risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Sanitam Partners LLC report in its Form 4 for MTNB?
Sanitam Partners LLC reported dispositions of Series C Convertible Preferred Stock and warrants on June 10, 2026 as part of an internal restructuring distribution to its members.
What warrants of MTNB were affected in the Sanitam Partners LLC filing?
Sanitam Partners LLC disposed of 4,798,636 Warrants to Purchase Common Stock, each with a conversion or exercise price of $0.6446 per share and an expiration date of April 8, 2030.
Does Sanitam Partners LLC still beneficially own MTNB securities after this Form 4?
No. The filing states that after distributing its preferred stock and warrants to its members, Sanitam no longer beneficially owns any securities of Matinas BioPharma Holdings, Inc.
Was the MTNB Form 4 transaction a market sale or an internal transfer?
The Form 4 describes an internal distribution of preferred stock and warrants by Sanitam Partners LLC to its members, coded as an “other acquisition or disposition” (J), not a market purchase or sale.
AI-generated analysis. How Rhea-AI works. Not financial advice.
